Trial of a paclitaxel-coated balloon for femoropopliteal artery disease
K Rosenfield, MR Jaff, CJ White… - … England Journal of …, 2015 - Mass Medical Soc
Background The treatment of peripheral artery disease with percutaneous transluminal
angioplasty is limited by the occurrence of vessel recoil and restenosis. Drug-coated …
angioplasty is limited by the occurrence of vessel recoil and restenosis. Drug-coated …
[引用][C] Trial of a Paclitaxel-Coated Balloon for Femoropopliteal Artery Disease
K Rosenfield, MR Jaff, CJ White… - New England Journal …, 2015 - cir.nii.ac.jp
Trial of a Paclitaxel-Coated Balloon for Femoropopliteal Artery Disease | CiNii Research CiNii
国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 論文・データを …
国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 論文・データを …
Trial of a Paclitaxel-Coated Balloon for Femoropopliteal Artery Disease.
K Rosenfield, MR Jaff, CJ White… - The New England …, 2015 - europepmc.org
Background The treatment of peripheral artery disease with percutaneous transluminal
angioplasty is limited by the occurrence of vessel recoil and restenosis. Drug-coated …
angioplasty is limited by the occurrence of vessel recoil and restenosis. Drug-coated …
Trial of a Paclitaxel-Coated Balloon for Femoropopliteal Artery Disease
K Rosenfield, MR Jaff, CJ White, K Rocha-Singh… - 2015 - pubmed.ncbi.nlm.nih.gov
Background The treatment of peripheral artery disease with percutaneous transluminal
angioplasty is limited by the occurrence of vessel recoil and restenosis. Drug-coated …
angioplasty is limited by the occurrence of vessel recoil and restenosis. Drug-coated …